WHAT YOU NEED TO KNOW On Friday, writing for The Hill, Matthew Lane, executive director of the Coalition Against Patent Abuse, called on Congress to reexamine the Orphan Drug Act (ODA) and pass an in-case-of-emergency alternative. In his must-read op-ed, Lane examines how the ODA is ill-suited for addressing the global COVID-19 pandemic and highlights the […]

Continue Reading

IN CASE YOU MISSED IT: Recently, The Hill published a timely op-ed by Matthew Lane, executive director of the Coalition Against Patent Abuse.  Lane penned this piece amidst the COVID-19 pandemic to highlight the need to make sure our drug laws are working to encourage innovation and public-private partnerships for the development of needed drugs while preventing […]

Continue Reading

WHAT YOU NEED TO KNOW This week, the Coalition Against Patent Abuse submitted comments to the FDA/FTC Workshop on Competitive Marketplace for Biosimilars. The FDA and FTC have an important role to play in promoting competition in the pharmaceutical marketplace and encouraging the implementation of sound drug pricing policy that leads to lower prescription drug prices for […]

Continue Reading

By Matthew Lane, Executive Director of the Coalition Against Patent Abuse (CAPA) On March 9, 2020, the Food and Drug Administration (FDA) and Federal Trade Commission (FTC) held a public workshop to discuss their collaborative efforts to support appropriate adoption of biosimilars, discourage false or misleading statements about biosimilars, and deter anticompetitive behaviors in the […]

Continue Reading

WASHINGTON, DC: On the 10th anniversary of the Biologics Price Competition and Innovation Act (BPCIA) that created biosimilars, The ERISA Industry Committee (ERIC) released a study on the potential savings employers and employees could have with increased biosimilars in the marketplace.  Inside Health Politicscovered the study which found that biologics – the most expensive class of […]

Continue Reading